Graham J, Xuan D, Luthra R, Borker R, Earnshaw SE, Lim J. Budget impact analysis of afatinib for the first-line treatment of metastatic non-small cell lung cancer patients with epidermal growth factor receptor exon 19 deletion mutations in a U.S. health plan. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S30.